ASH 2022 Preliminary Safety & Efficacy From the Phase 2 APEX Study of Bezuclastinib, a Novel, Highly Selective, Potent KIT D816V TKI, in Adults With Advanced Systemic Mastocytosis
By
ASH 2022 Conference Coverage
FEATURING
Daniel J. DeAngelo
By
ASH 2022 Conference Coverage
FEATURING
Daniel J. DeAngelo
Login to view comments.
Click here to Login